FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281650680> ?p ?o ?g. }

• W4281650680 endingPage "2928.e5" @default.
• W4281650680 startingPage "2920" @default.
• W4281650680 abstract "Severe cutaneous adverse reactions related to first-line antituberculosis drugs are associated with high mortality and long-term morbidity. Oral sequential drug challenge, as a form of drug provocation testing, helps to salvage therapy by identifying culprit drugs but is associated with risk and is costly. IFN-γ enzyme-linked immune absorbent spot (ELISpot), an adjunctive in vitro diagnostic tool, may help to guide risk-stratification approaches. To determine the diagnostic accuracy of IFN-γ ELISpot against full-dose sequential drug challenge, we analyzed samples collected prospectively at multiple time points in 32 patients with first-line antituberculosis drug‒associated severe cutaneous adverse reaction (81% HIV infected, 25 with drug reaction with eosinophilia and systemic symptoms, and 7 with Stevens‒Johnson syndrome/toxic epidermal necrolysis). Sensitivity of IFN-γ ELISpot was 33% (4 of 12), 13% (1 of 8), 11% (1 of 9), and 0% (0 of 4) for rifampicin, isoniazid, pyrazinamide, and ethambutol, respectively (positivity threshold ≥50 spot forming units/million cells). Specificity was 100% for all the four drugs. Rifampicin IFN-γ ELISpot sensitivity increased to 58% (7 of 12) if a threshold of 20 spot forming units was used and to 75% (3 of 4) when restricted to samples <12 weeks after acute severe cutaneous adverse reaction event; specificity remained 100% for both. IFN-γ ELISpot offers adequate risk stratification of rifampicin severe cutaneous adverse reaction using acute samples and lowered threshold for positivity. Given the low sensitivity of IFN-γ ELISpot for other first-line antituberculosis drugs, additional optimization is needed to improve risk-stratification potential. Severe cutaneous adverse reactions related to first-line antituberculosis drugs are associated with high mortality and long-term morbidity. Oral sequential drug challenge, as a form of drug provocation testing, helps to salvage therapy by identifying culprit drugs but is associated with risk and is costly. IFN-γ enzyme-linked immune absorbent spot (ELISpot), an adjunctive in vitro diagnostic tool, may help to guide risk-stratification approaches. To determine the diagnostic accuracy of IFN-γ ELISpot against full-dose sequential drug challenge, we analyzed samples collected prospectively at multiple time points in 32 patients with first-line antituberculosis drug‒associated severe cutaneous adverse reaction (81% HIV infected, 25 with drug reaction with eosinophilia and systemic symptoms, and 7 with Stevens‒Johnson syndrome/toxic epidermal necrolysis). Sensitivity of IFN-γ ELISpot was 33% (4 of 12), 13% (1 of 8), 11% (1 of 9), and 0% (0 of 4) for rifampicin, isoniazid, pyrazinamide, and ethambutol, respectively (positivity threshold ≥50 spot forming units/million cells). Specificity was 100% for all the four drugs. Rifampicin IFN-γ ELISpot sensitivity increased to 58% (7 of 12) if a threshold of 20 spot forming units was used and to 75% (3 of 4) when restricted to samples <12 weeks after acute severe cutaneous adverse reaction event; specificity remained 100% for both. IFN-γ ELISpot offers adequate risk stratification of rifampicin severe cutaneous adverse reaction using acute samples and lowered threshold for positivity. Given the low sensitivity of IFN-γ ELISpot for other first-line antituberculosis drugs, additional optimization is needed to improve risk-stratification potential." @default.
• W4281650680 created "2022-06-13" @default.
• W4281650680 creator A5009308092 @default.
• W4281650680 creator A5009435222 @default.
• W4281650680 creator A5024335560 @default.
• W4281650680 creator A5028219887 @default.
• W4281650680 creator A5031509709 @default.
• W4281650680 creator A5031703873 @default.
• W4281650680 creator A5053677354 @default.
• W4281650680 creator A5057215968 @default.
• W4281650680 creator A5080985934 @default.
• W4281650680 date "2022-11-01" @default.
• W4281650680 modified "2023-10-16" @default.
• W4281650680 title "IFN-γ ELISpot in Severe Cutaneous Adverse Reactions to First-Line Antituberculosis Drugs in an HIV Endemic Setting" @default.
• W4281650680 cites W102662015 @default.
• W4281650680 cites W11309145 @default.
• W4281650680 cites W1493299210 @default.
• W4281650680 cites W1973783655 @default.
• W4281650680 cites W1991957921 @default.
• W4281650680 cites W1998660799 @default.
• W4281650680 cites W2005673189 @default.
• W4281650680 cites W2008784877 @default.
• W4281650680 cites W2017472781 @default.
• W4281650680 cites W2037985084 @default.
• W4281650680 cites W2041779672 @default.
• W4281650680 cites W2043270048 @default.
• W4281650680 cites W2045391651 @default.
• W4281650680 cites W2053107833 @default.
• W4281650680 cites W2055561436 @default.
• W4281650680 cites W2067978628 @default.
• W4281650680 cites W2071254264 @default.
• W4281650680 cites W2077822943 @default.
• W4281650680 cites W2089780776 @default.
• W4281650680 cites W2093042860 @default.
• W4281650680 cites W2108554865 @default.
• W4281650680 cites W2109028417 @default.
• W4281650680 cites W2119260702 @default.
• W4281650680 cites W2134537227 @default.
• W4281650680 cites W2144010669 @default.
• W4281650680 cites W2154396724 @default.
• W4281650680 cites W2154962788 @default.
• W4281650680 cites W2161934696 @default.
• W4281650680 cites W2169327920 @default.
• W4281650680 cites W2317624504 @default.
• W4281650680 cites W2336894756 @default.
• W4281650680 cites W2466833946 @default.
• W4281650680 cites W2614087518 @default.
• W4281650680 cites W2804807819 @default.
• W4281650680 cites W2955016485 @default.
• W4281650680 cites W2955763017 @default.
• W4281650680 cites W2956038859 @default.
• W4281650680 cites W2971142980 @default.
• W4281650680 cites W3081024630 @default.
• W4281650680 cites W3092581372 @default.
• W4281650680 cites W3110088614 @default.
• W4281650680 cites W3120814801 @default.
• W4281650680 cites W3189834894 @default.
• W4281650680 cites W3191713454 @default.
• W4281650680 cites W4290450988 @default.
• W4281650680 cites W4299856298 @default.
• W4281650680 doi "https://doi.org/10.1016/j.jid.2022.05.1059" @default.
• W4281650680 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35659939" @default.
• W4281650680 hasPublicationYear "2022" @default.
• W4281650680 type Work @default.
• W4281650680 citedByCount "5" @default.
• W4281650680 countsByYear W42816506802022 @default.
• W4281650680 countsByYear W42816506802023 @default.
• W4281650680 crossrefType "journal-article" @default.
• W4281650680 hasAuthorship W4281650680A5009308092 @default.
• W4281650680 hasAuthorship W4281650680A5009435222 @default.
• W4281650680 hasAuthorship W4281650680A5024335560 @default.
• W4281650680 hasAuthorship W4281650680A5028219887 @default.
• W4281650680 hasAuthorship W4281650680A5031509709 @default.
• W4281650680 hasAuthorship W4281650680A5031703873 @default.
• W4281650680 hasAuthorship W4281650680A5053677354 @default.
• W4281650680 hasAuthorship W4281650680A5057215968 @default.
• W4281650680 hasAuthorship W4281650680A5080985934 @default.
• W4281650680 hasBestOaLocation W42816506802 @default.
• W4281650680 hasConcept C126322002 @default.
• W4281650680 hasConcept C142724271 @default.
• W4281650680 hasConcept C16005928 @default.
• W4281650680 hasConcept C167672396 @default.
• W4281650680 hasConcept C197934379 @default.
• W4281650680 hasConcept C203014093 @default.
• W4281650680 hasConcept C2776228421 @default.
• W4281650680 hasConcept C2778607973 @default.
• W4281650680 hasConcept C2779053233 @default.
• W4281650680 hasConcept C2780425889 @default.
• W4281650680 hasConcept C2780664588 @default.
• W4281650680 hasConcept C2781069245 @default.
• W4281650680 hasConcept C71924100 @default.
• W4281650680 hasConcept C8891405 @default.
• W4281650680 hasConcept C98274493 @default.
• W4281650680 hasConceptScore W4281650680C126322002 @default.
• W4281650680 hasConceptScore W4281650680C142724271 @default.
• W4281650680 hasConceptScore W4281650680C16005928 @default.
• W4281650680 hasConceptScore W4281650680C167672396 @default.
• W4281650680 hasConceptScore W4281650680C197934379 @default.

• next